Ruoxue Cai^1,#, Shuyi Hu^2,#, Feiyang Li², Huanhuan Sha^3,*, Guoren Zhou^2,*, Ying Fang³

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.070893 - 19 January 2026

Abstract Objective: To determine whether immunotherapy can bring new hope for patients with limited-stage small-cell lung cancer (LS-SCLC). We conducted this retrospective study to evaluate whether immunotherapy can achieve better efficacy in LS-SCLC patients. Methods: We evaluated 122 LS-SCLC patients who received concurrent chemoradiotherapy (CCRT) or sequential chemoradiotherapy (SCRT) (Group A) and immunotherapy combined with CCRT/SCRT followed by immunotherapy (Group B), to assess the objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). Factors affecting prognosis were also explored using Cox analysis. The prognosis of patients with type 2 diabetes and patients with… More >

Keiko Yanagihara^1,*, Masato Yoshida², Kensaku Awaji², Tamami Yamakawa¹, Sena Kato¹, Miki Tamura¹, Koji Nagata³

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.073891 - 30 December 2025

Abstract Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have transformed the management of hormone receptor–positive/HER2–negative (HR+/HER2–) advanced breast cancer, yet evidence for elderly or poor-performance patients remains limited. This study examined real-world outcomes of palbociclib plus endocrine therapy in Asian patients, with additional subgroup analyses by age and performance status. Methods: We retrospectively analyzed 46 consecutive Asian patients with recurrent or de novo HR+/HER2− breast cancer treated with first-line palbociclib plus ET between April 2021 and March 2025. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rate (ORR), disease control rate (DCR), and safety.… More >

Cheng-Hsun Chuang^1,2,3,#, Ping-Kun Tsai^3,4,5,6,#, Shih-Wen Kao^7,8, Yu-Hsun Wang^8,9,*, Chao-Bin Yeh^1,2,3,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.072875 - 30 December 2025

Abstract Background: To determine whether initiating a glucagon-like peptide-1 receptor agonist (GLP-1 RA) within 3 months of type 2 diabetes (T2DM) diagnosis alters the subsequent risk of overall and site-specific cancer and whether this association differs by baseline body-mass index (BMI). Methods: This retrospective cohort study used electronic health records from the TriNetX U.S. research network. Adults aged 20 years or older diagnosed with T2DM between 2016 and 2024 were included if they received any hypoglycemic agents within 3 months before and after diagnosis. Following 1:1 propensity score matching, both the GLP-1 RA user and non-user… More > Graphic Abstract

Zhongyun Tang^1,2,3, Hanyi Xu², Haiyang Hu^1,3,*

CMC-Computers, Materials & Continua, Vol.86, No.2, pp. 1-29, 2026, DOI:10.32604/cmc.2025.070616 - 09 December 2025

Abstract With the deep integration of smart manufacturing and IoT technologies, higher demands are placed on the intelligence and real-time performance of industrial equipment fault detection. For industrial fans, base bolt loosening faults are difficult to identify through conventional spectrum analysis, and the extreme scarcity of fault data leads to limited training datasets, making traditional deep learning methods inaccurate in fault identification and incapable of detecting loosening severity. This paper employs Bayesian Learning by training on a small fault dataset collected from the actual operation of axial-flow fans in a factory to obtain posterior distribution. This More >

Khanh Toan Nguyen^1,*, Thi Huong Pham^1,2, Van Lam Ngo¹, Thi Thuy My Nguyen¹, Thi Dao Nguyen¹, Khanh Hung Truong¹, Van Nhat Nguyen¹, Van Thanh Le¹, Ba Duc Ho¹, Thi Phuong Thao Nguyen¹, Thi Ha Phuong Nguyen¹, Thi My Linh Dinh¹, Thi Hong Anh Vo¹, Thi Thuy Phan¹, Thi Hai Yen Le¹, Thi Nhung Ngo¹, Khanh Ha Nguyen¹

Oncology Research, Vol.33, No.12, pp. 4013-4028, 2025, DOI:10.32604/or.2025.069281 - 27 November 2025

Abstract Objective: Patients with stage III non-small cell lung cancer (NSCLC) present with a heterogeneous disease profile and often require multifaceted treatment strategies. This research aimed to investigate the demographic features, therapeutic patterns, and survival outcomes of such patients in Vietnam. Methods: A retrospective descriptive study was conducted on 731 patients diagnosed with stage III NSCLC American Joint Committee on Cancer (AJCC) 8th edition, at Nghe An Oncology Hospital from January 2018 to August 2024. Descriptive statistics summarized baseline and treatment characteristics. We calculated progression-free survival (PFS) and overall survival (OS) through the Kaplan–Meier approach and… More >

Xizhou Zhang^1,#, Zetao Zhang^1,#, Jianguang Lin², Jiarong Yi³, Xuxiazi Zou³, Jikun Feng³, Guangsheng Huang¹, Bingfeng Chen¹, Junxi Long¹, Fengjia Wu³, Feng Ye^3,*, Haoming Wu^1,*

Oncology Research, Vol.33, No.9, pp. 2529-2547, 2025, DOI:10.32604/or.2025.065029 - 28 August 2025

Abstract Background: Breast cancer remains a leading cause of morbidity and mortality among women worldwide, with significant geographic disparities in its impact. While human epidermal growth factor receptor 2 (HER2)-targeted therapies, such as trastuzumab, have improved outcomes for HER2-positive breast cancer, challenges like therapy resistance persist, highlighting the need for novel treatments. Recent developments in antibody-drug conjugates (ADCs), particularly disitamab vedotin (RC48), show promising efficacy in targeting both HER2-positive and HER2-low expression tumors, warranting further investigation through real-world studies to assess its broader clinical applicability. Method: This retrospective, multicenter observational study evaluated the real-world efficacy and… More >

Xi Qin^1,#, Yulan Liu^1,#, Lin Zhu², Yunyan Mo¹, Jing Zhang³, Zhuchun Jiang⁴, Dongning Huang⁵, Xinrong Hu⁶, Jingzhang Li⁷, Quanfang Chen⁸, Feng Xue^1,*

Oncology Research, Vol.33, No.9, pp. 2451-2462, 2025, DOI:10.32604/or.2025.064119 - 28 August 2025

Abstract Background: The use of third-generation different tyrosine kinase inhibitors (TKIs) is considered the most effective option for treating advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) mutations. However, there is limited information on the efficacy and safety of aumolertinib in patients remains these cases. Methods: The clinical records of patients receiving aumolertinib as first-line therapy across four hospitals in the Guangxi Zhuang Autonomous Region from April 2020 to December 2021 were retrospectively analyzed, using progression-free survival (PFS) as the primary endpoint and overall survival (OS) representing the secondary endpoint. Adverse events… More >

KHANH TOAN NGUYEN^*, THI HUONG PHAM, VAN LAM NGO, VAN TUAN BUI, VAN NHAT NGUYEN, THI PHUONG THAO NGUYEN, THI KHANH HA NGUYEN, THI THUY VAN NGUYEN

Oncology Research, Vol.33, No.7, pp. 1667-1677, 2025, DOI:10.32604/or.2025.061905 - 26 June 2025

Abstract Aims: The study aimed to evaluate the effectiveness and adverse events of tyrosine kinase inhibitors (TKIs) in the first-line treatment of advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Methods: A retrospective study on advanced NSCLC patients with EGFR mutations treated with TKIs as a first-line therapy at Nghe An Oncology Hospital, Vietnam between January 2017 and August 2023. The primary endpoints included objective response rate, progression-free survival, and tolerability. The secondary endpoint was overall survival. Results: A total of 211 patients received first-line treatment with Erlotinib (n = 74), Gefitinib (n… More >

Yu Zhou¹, Eneko Osaba², Xiao Zhang^3,*

CMC-Computers, Materials & Continua, Vol.84, No.1, pp. 237-242, 2025, DOI:10.32604/cmc.2025.066663 - 09 June 2025

Abstract This article has no abstract. More >

Zachariah Taylor^1,*, Kayla Meyer², Danielle Terrenzio², Ryan Wong³, Sharon Larson⁴, Stephanie Kjelstrom⁴, Natalina Contoreggi⁵, Laurence Belkoff^1,6, Ilia Zeltser^1,6

Canadian Journal of Urology, Vol.32, No.1, pp. 21-27, 2025, DOI:10.32604/cju.2025.064705 - 20 March 2025

Abstract Purpose: While the mental health impact of a prostate cancer diagnosis, including low-risk prostate cancer, is well-documented, the effect of pre-existing anxiety and/or depression on adherence to active surveillance protocols in low-risk prostate cancer patients remains unclear. This study assessed the association between prior anxiety and/or depression and active surveillance adherence in men with low-risk prostate cancer. Methods: We conducted a retrospective, multicenter study involving 426 men diagnosed with low-risk prostate cancer who were recommended active surveillance as the primary management strategy. Active surveillance adherence was defined by completion of both a prostate-specific antigen test… More >